Business Context and Reporting Period
P3 Health Partners Inc. filed a Form 8-K concerning its Nasdaq continued-listing compliance. The reported event occurred on May 18, 2022; the filing was signed May 24, 2022. The company’s delayed reports relate to the year ended December 31, 2021 and the quarter ended March 31, 2022.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics. The delayed Form 10-K and Form 10-Q were not included in the provided text.
Material Changes and Listing Status
- Nasdaq notified the company that it was not in compliance with Listing Rule 5250(c)(1) because it had not timely filed its 2021 Form 10-K and first-quarter 2022 Form 10-Q.
- The notice had no immediate effect on the listing or trading of the company’s Class A common stock on the Nasdaq Capital Market.
- The company had until July 18, 2022, to submit a plan to regain compliance.
- If Nasdaq accepted the plan, it could grant up to 180 additional calendar days from the prescribed due date of the 2021 Form 10-K, or through September 27, 2022, to regain compliance.
Outlook, Management Commentary, Risks and Unusual Items
Management stated that it was working diligently to complete and file the delayed periodic reports and expected to file both before July 18, 2022. If filed by that date, the company stated that submitting a formal compliance plan would not be necessary.
The principal risk is potential adverse Nasdaq action if the company does not timely regain compliance, although the notice itself did not immediately suspend or delist the securities. The filing provides no additional financial guidance, contingencies, or operating outlook.
Investor Verification Priorities
- Verify the actual filing dates and contents of the 2021 Form 10-K and first-quarter 2022 Form 10-Q.
- Confirm whether the company regained compliance with Nasdaq Listing Rule 5250(c)(1) by the applicable deadlines.
- Review the delayed reports for financial results, liquidity, debt obligations, internal controls, and any going-concern or audit matters.
- Review Nasdaq correspondence for any subsequent extension, warning, suspension, or delisting determination.